Business Context and Reporting Period
Skye Bioscience, Inc. (SKYE) filed a Form 8-K on May 13, 2026, regarding a listing deficiency notice received from The Nasdaq Stock Market LLC. The Company is incorporated in Nevada and its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
Based on the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026:
- Stockholders' Equity: $9,011,804
- Minimum Equity Requirement: $10,000,000 (Nasdaq Listing Rule 5450(b)(1)(A))
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes and Listing Status
The Company is currently non-compliant with Nasdaq's minimum stockholders' equity standard. The notice has no immediate effect on the listing or trading of the common stock, which will continue to trade under the symbol "SKYE".
Outlook, Risks, and Contingencies
Compliance Timeline:
- Plan Submission Deadline: June 29, 2026 (45 calendar days from notice).
- Compliance Extension: If a plan is accepted, the Company may receive up to 180 calendar days (until November 9, 2026) to evidence compliance.
- Appeal Rights: If the plan is not accepted, the Company retains the right to appeal, during which the stock remains listed.
Risks and Management Commentary: The Company is evaluating various alternative courses of action to regain compliance. Management explicitly states there can be no assurance that the Company will be able to regain compliance with the minimum stockholders' equity requirement or maintain compliance with other listing requirements.
Investor Verification Checklist
- Verify the specific plan Skye Bioscience intends to submit by June 29, 2026, to restore stockholders' equity to $10,000,000.
- Monitor the Company's Form 10-Q for the quarter ended March 31, 2026, for detailed financial statements regarding revenue, cash flow, and debt levels.
- Track any subsequent 8-K filings regarding the acceptance or rejection of the compliance plan by Nasdaq.
- Assess the likelihood of delisting if the Company fails to meet the equity threshold by November 9, 2026.